



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re* Application of )  
 ) Group Art Unit: 1614  
Torrance *et al.* )  
 ) Examiner: N/A  
Serial No. 09/961,407 )  
 )  
Filed: September 25, 2001 ) Atty. Dkt. No. 001107.00140

#5  
RECEIVED  
MAR 14 2002  
TECH CENTER 1600/2900

For: **USE OF ISOGENIC HUMAN CANCER CELLS FOR HIGH-THROUGHPUT SCREENING AND DRUG DISCOVERY**

**INFORMATION DISCLOSURE STATEMENT**

Director of Patents and Trademarks  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application and a copy of each of the identified documents. It is believed no fee is required in connection with this filing. However, if a fee is required, please charge our Deposit Account No. 19-0733.

Consideration of this information is respectfully requested.


Respectfully submitted,

Dated: March 11, 2002

By:

Amy M. Rocklin  
Reg. No. 47,033

Banner & Witcoff, Ltd.  
1001 G Street, N.W., Eleventh Floor  
Washington, D.C. 20001-4597  
(202) 508-9100



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/961,407
Filing Date	September 25, 2001
First Named Inventor	Christopher TORRANCE, et al
Group Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	001107.00140

Total Number of Pages in This Submission

### ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) \_\_\_\_\_

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):  
**Form 1449**  
**Cited References (4)**

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Amy M. Rocklin, Reg. No. 47,033
Signature	
Date	March 11, 2002

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature


Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1614

MAR 14 2002  
RECEIVED  
1600/2900

RECEIVED



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submit this form for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/961,407
Filing Date	September 25, 2001
First Named Inventor	Christopher J. Torrance
Group Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	001107.00140

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	/	JENKINS et al., A novel cell-based assay for the evaluation of anti-ras compounds, Br. J. Cancer, 1993, 69, 856-61	
	/	KAIN, Green fluorescent protein (GFP): applications in cell-based assays for drug discovery, DDT, 1999, 4, 304-12	
	/	CORBLEY et al., A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors, Int. J. Cancer, 1996, 66, 753-9	
	/	STRATOWA et al., A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity, Anti-Cancer Drug Design, 1999, 14, 393-402	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 14 2002

RECEIVED